Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

TB test accepted for ‘exceptional private use’
Actiphage is a six-hour test that can identify the presence of live mycobacteria in blood or milk samples.
BVA welcomes move that could improve testing accuracy

A novel test for bovine TB that is more sensitive than previous methods has been accepted for ‘exceptional private use’ in England.

Actiphage is a six-hour test that can identify the presence of live mycobacteria in blood or milk samples. The currently approved skin test for bovine TB assesses the animal’s response to the bacteria and results take 72 hours.

Under the new ‘exceptional private use’ protocol, Actiphage can be used on a small number of large, persistently-infected herds. Before it can be given the go-ahead for veterinary use, however, it will need to go through further trials.

The news has been welcomed by the British Veterinary Association (BVA). BVA president John Fishwick said:

“We welcome any test that could improve the accuracy of diagnosing bovine TB and it is heartening to hear that this new test could potentially provide quicker, more convenient results.

“With any TB test, it is absolutely crucial that its sensitivity, specify and performance are fully understood and it is reassuring that the Animal and Plant Health Agency have authorised the exceptional private use of this test to it will be used appropriately at this stage of its development.

“TB testing is an important tool that can help achieve the long-term goal of TB eradication and must be part of a comprehensive toolkit of measures.”

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
Free webinar explores congenital heart disease in dogs

A free webinar is to provide veterinary professionals, dog breeders and pet owners an new insights into congenital heart disease.

Chris Linney, a cardiology specialist and Veterinary Cardiovascular Society (VSC) member, will present the webinar from 7.00pm to 8.30pm on Wednesday, 12 November.

Dr Linney will explore the types, causes and clinical presentation of congenital heart conditions. This will include diagnostic approaches, treatment pathways and emerging research opportunities.

The session is the third to be organised by The Kennel Club, with the VCS, following an introductory webinar and a talk on acquired heart disease. Dr Linney's webinar consists of a one-hour presentation, followed by a 30-minute question and answer session.

Dr Linney said: "This webinar will be an opportunity to deepen understanding - not just of the diseases themselves, but of how breeders, vets and owners can work together to support affected dogs and improve outcomes for future generations."

Click here to register for the webinar.